BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12387706)

  • 1. Fabry disease: recent advances in enzyme replacement therapy.
    Germain DP
    Expert Opin Investig Drugs; 2002 Oct; 11(10):1467-76. PubMed ID: 12387706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fabry's disease (alpha-galactosidase-A deficiency): physiopathology, clinical signs, and genetic aspects].
    Germain DP
    J Soc Biol; 2002; 196(2):161-73. PubMed ID: 12360745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
    Germain DP
    J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the management of Anderson-Fabry disease: enzyme replacement therapy.
    Pastores GM; Thadhani R
    Expert Opin Biol Ther; 2002 Mar; 2(3):325-33. PubMed ID: 11890871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease.
    Germain DP
    Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy in Fabry disease: clinical implications.
    Breunig F; Knoll A; Wanner C
    Curr Opin Nephrol Hypertens; 2003 Sep; 12(5):491-5. PubMed ID: 12920395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.
    Mignani R; Cagnoli L
    J Nephrol; 2004; 17(3):354-63. PubMed ID: 15365954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabry disease: molecular genetics of the inherited nephropathy.
    Desnick RJ; Astrin KH; Bishop DF
    Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fabry disease. Clinical and genetic aspects. Therapeutic perspectives].
    Germain DP
    Rev Med Interne; 2000 Dec; 21(12):1086-103. PubMed ID: 11191676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabry disease in the era of enzyme replacement therapy: a renal perspective.
    Cho ME; Kopp JB
    Pediatr Nephrol; 2004 Jun; 19(6):583-93. PubMed ID: 15064943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations.
    Caballero L; Climent V; Hernández-Romero D; Quintanilla MA; de la Morena G; Marín F
    Curr Med Chem; 2010; 17(16):1679-89. PubMed ID: 20345350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of Fabry disease].
    Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
    Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy for Fabry disease, an inherited nephropathy.
    Desnick RJ; Banikazemi M; Wasserstein M
    Clin Nephrol; 2002 Jan; 57(1):1-8. PubMed ID: 11837797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anderson-Fabry disease in Austria.
    Lorenz M; Hauser AC; Püspök-Schwarz M; Kotanko P; Arias I; Zodl H; Kramar R; Paschke E; Voigtländer T; Sunder-Plassmann G
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):235-40. PubMed ID: 12778775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The heart in Fabry's disease.
    Sheppard MN
    Cardiovasc Pathol; 2011; 20(1):8-14. PubMed ID: 19919901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
    Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
    G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
    Banikazemi M; Ullman T; Desnick RJ
    Mol Genet Metab; 2005 Aug; 85(4):255-9. PubMed ID: 15939645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
    Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
    Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.